文献速递妇科

游离DNA在诊断卵巢癌中相对于临床和超声信息的附加价值

Added value of cell-free DNA over clinical and ultrasound information for diagnosing ovarian cancer.
PubMed 文献 · Ultrasound Obstet Gynecol · 2025-08-19

这项前瞻性队列研究纳入526例因附件肿块拟手术的患者,在三个肿瘤转诊中心连续招募,评估将基于游离DNA的评分(全基因组Z评分和核小体评分)加入ADNEX模型的临床和超声预测因子后,对卵巢恶性肿瘤风险的附加诊断价值。结果显示,加入cfDNA评分后似然比有统计学意义,但AUC仅分别增加0.013和0.003,净获益、敏感性和特异性相似;在10%风险阈值下,每额外获得一例真阳性需至少453例患者。结论认为cfDNA评分虽具统计学意义,但临床效用有限。

要点

  • 在ADNEX模型中加入cfDNA评分后,AUC仅分别增加0.013(不含CA125)和0.003(含CA125),临床效用有限。
  • 在推荐10%风险阈值下,加入cfDNA评分的净获益增加仅为0.0017和0.0020,敏感性和特异性与未加入时相似。
  • 据估计,在10%风险阈值下每额外获得一例真阳性结果至少需要453例患者。

核心结论

  • 尽管具有统计学意义,但基于cfDNA的生物标志物评分在已建立的临床和超声ADNEX预测因子之外,对于区分良性和恶性卵巢肿块的临床效用有限。

研究设计与样本

  • 前瞻性队列研究,在三个肿瘤转诊中心连续招募526例因附件肿块拟手术的患者,所有患者接受经阴道超声检查,附件肿块按国际卵巢肿瘤分析术语和定义描述。
  • 从术前血浆样本中提取cfDNA并计算全基因组Z评分和核小体评分,分别拟合仅含ADNEX预测因子和加入cfDNA评分的逻辑回归模型。
  • 报告似然比、受试者工作特征曲线下面积(AUC)、敏感性、特异性和5%至40%阈值之间的净获益,以评估模型区分良恶性卵巢肿块的诊断性能。

主要发现

  • 研究纳入272例良性、86例交界性、36例I期浸润性、113例II-IV期浸润性和19例继发性转移性肿瘤。
  • 将cfDNA评分加入ADNEX模型的似然比具有统计学意义(不含CA125的ADNEX模型P<0.001;含CA125的ADNEX模型P=0.001)。
  • 加入cfDNA生物标志物后AUC的增加分别为:不含CA125的ADNEX模型增加0.013,含CA125的ADNEX模型增加0.003。
  • 所有模型的净获益、敏感性和特异性相似。
  • 在推荐10%估计恶性风险阈值下,加入cfDNA评分后净获益的增加分别为不含CA125的ADNEX模型0.0017和含CA125的ADNEX模型0.0020。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We previously proposed two cell-free (cf) DNA-based scores (genome-wide Z-score and nucleosome score) as candidate non-invasive biomarkers to further improve the presurgical diagnosis of ovarian malignancy. We aimed to investigate the added value of these cfDNA-based scores in combination with the clinical and ultrasound predictors of the Assessment of Different NEoplasias in the adneXa (ADNEX) model to estimate the risk of ovarian malignancy. METHODS: In this prospective cohort study, 526 patients with an adnexal mass scheduled for surgery were recruited consecutively in three oncology referral centers. All patients underwent a transvaginal ultrasound examination, and adnexal masses were described according to the International Ovarian Tumor Analysis terms and definitions. cfDNA was extracted from preoperative plasma samples and genome-wide Z-scores and nucleosome scores were calculated. Logistic regression models were fitted for ADNEX predictors alone and after inclusion of the cfDNA-based scores. We report likelihood ratios, area under the receiver-operating-characteristics curve (AUC), sensitivity, specificity and net benefit for thresholds between 5% and 40%, to assess the diagnostic performance of the models in discriminating between benign and malignant ovarian masses. RESULTS: The study included 272 benign, 86 borderline, 36 Stage-I invasive, 113 Stage-II-IV invasive, and 19 secondary metastatic tumors. The likelihood ratios for adding the cfDNA-based scores to the ADNEX model were statistically significant (P < 0.001 for ADNEX without CA 125; P = 0.001 for ADNEX including CA 125). The accompanying increases in AUC were 0.013 when the cfDNA biomarkers were added to the ADNEX model without CA 125, and 0.003 when added to the ADNEX model including CA 125. Net benefit, sensitivity and specificity were similar for all models. The increase in net benefit at the recommended 10% threshold estimated risk of malignancy when adding the cfDNA-based scores was 0.0017 and 0.0020, respectively, for the ADNEX model without CA 125 and the ADNEX model with CA 125. According to these results, adding cfDNA markers would require at least 453 patients per additional true-positive test result at the 10% risk threshold. CONCLUSION: Although statistically significant, cfDNA-based biomarker scores have limited clinical utility in addition to established clinical and ultrasound-based ADNEX predictors for discriminating between benign and malignant ovarian masses. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Vanderstichele A, Ceusters J, Fischerova D, et al. Added value of cell-free DNA over clinical and ultrasound information for diagnosing ovarian cancer. Ultrasound Obstet Gynecol. 2025. PMID: 40829165. doi:10.1002/uog.29314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。